<unk>  (trade name Ilumya (US)/Ilumetri (European Union)) is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.<unk>  was designed to block interleukin-23 (IL-23), a cytokine that plays a key role in managing the immune system and autoimmune disease.
Tildrakizumab
Brolucizumab
Risankizumab
Mogamulizumab
Etaracizumab
Caplacizumab
Ixekizumab
Crizanlizumab